| 625390-08-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• CAS: 625390-08-1
• 化学式: C₅₃H₉₄N₂O₁₇Si
• 分子量: 1059.42
• InChiKey: WSASHXBRQGQPMC-GHNPGNIHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.88
• 重原子数：
  73.0
• 可旋转键数：
  16.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  225.87
• 氢给体数：
  2.0
• 氢受体数：
  19.0

反应信息

• 作为反应物：
  描述：

  以 甲醇 为溶剂， 反应 8.0h， 以89%的产率得到
  参考文献：
  名称：

  [EN] 6-11 BICYCLIC KETOLIDE DRIVATIVES
  [FR] DERIVES DE KETOLIDE 6-11 BICYCLIQUES

  摘要：

  本发明公开了具有以下结构的化合物I，或其药学上可接受的盐、酯或前药：Formule (I)，其具有抗菌性能。本发明还涉及包括上述化合物的药物组合物，用于给需要抗生素治疗的受试者使用。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。

  公开号：

  WO2005061526A1
• 作为产物：
  描述：

  叔丁基二甲基氯硅烷 在 sodium hydroxide 、 tris(dibenzylideneacetone)dipalladium (0) 、 四丁基硫酸氢铵 、 sodium hydride 、 1,4-双(二苯基膦)丁烷 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 20.0h， 生成
  参考文献：
  名称：

  Synthesis of Novel 6,11-O-Bridged Bicyclic Ketolides via a Palladium-Catalyzed Bis-allylation

  摘要：

  A bridging chemistry process was developed to form an ether bridge between 6-O and 11-O of erythromycin A via a tandem or stepwise palladium-catalyzed bis-pi-allylation. By applying this bridging process, new 6,11-O-bridged bicyclic ketolides (BBKs) were synthesized. These BBKs showed good antibacterial activities against the macrolide-susceptible strains as well as mef-resistant strains and served as a good core for further modifications to study the structure-activity relationship (SAR) and to overcome bacterial resistance.

  DOI：

  10.1021/ol048336r

文献信息

• [EN] 6-11 BICYCLIC KETOLIDE DERIVATIVES<br/>[FR] DERIVES KETOLIDES BICYCLIQUES 6-11
  申请人：ENANTA PHARM INC

  公开号：WO2005061525A1

  公开（公告）日：2005-07-07

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了具有以下结构的化合物，或其药学上可接受的盐、酯或前药：(I)，这些化合物具有抗菌性能。本发明还涉及包含上述化合物的药物组合物，用于给需要抗生素治疗的受试者进行治疗。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
• [EN] BRIDGED MACROCYCLIC COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF<br/>[FR] COMPOSES MACROCYCLIQUES PONTES ET PROCEDES DE PREPARATION DESDITS COMPOSES
  申请人：ENANTA PHARM INC

  公开号：WO2005080408A1

  公开（公告）日：2005-09-01

  The present invention provides a method for preparing bridged macrocyclic compounds comprising the step of reacting a macrocyclic compound characterized by having at least two nucleophilic moieties with a bifunctional bridging reagent optionally in the presence of a catalyst, thereby producing a bridged macrocyclic product.

  本发明提供了一种制备桥联大环化合物的方法，包括以下步骤：将至少具有两个亲核基团的大环化合物与双功能桥接试剂反应，可选地在催化剂的存在下进行，从而产生桥联大环产物。
• Novel bicyclic 9a-azalide derivatives
  申请人：Or Sun Yat

  公开号：US20060069048A1

  公开（公告）日：2006-03-30

  The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了具有以下式I和II的化合物，或其药学上可接受的盐、酯或前药：具有抗菌特性。本发明还涉及包含上述化合物的药物组合物，用于治疗需要抗生素治疗的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。